BioNTech (NASDAQ:BNTX) COO Sierk Poetting Sells 50,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BioNTech Stock Down 2.8%

BioNTech stock traded down $3.04 during midday trading on Thursday, reaching $105.56. The company’s stock had a trading volume of 716,485 shares, compared to its average volume of 1,121,362. The stock’s 50-day simple moving average is $97.98 and its 200-day simple moving average is $101.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The stock has a market capitalization of $26.69 billion, a P/E ratio of -20.14 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The business had revenue of $1.06 billion during the quarter. On average, sell-side analysts expect that BioNTech SE Sponsored ADR will post -4.41 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BNTX. Royal Bank of Canada increased its holdings in shares of BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the period. NewEdge Advisors LLC purchased a new stake in shares of BioNTech in the first quarter worth about $167,000. Russell Investments Group Ltd. boosted its stake in shares of BioNTech by 368,800.0% in the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock worth $1,178,000 after buying an additional 11,064 shares during the last quarter. Natixis purchased a new stake in shares of BioNTech in the second quarter worth about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of BioNTech by 2.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after buying an additional 13,788 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on BNTX. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, March 25th. BMO Capital Markets decreased their price target on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research note on Wednesday, March 11th. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a research note on Monday, February 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $133.13.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.